Given the uncertainty regarding long-term safety of GH treatment, we employed the HypoCCS database to assess mortality and the incidence rates for cancer, myocardial infarction (MI), and stroke in adult GH-deficient patients who had received pediatric GH treatment. Here, GH1 is linked to myocardial infarction.